These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Allelic variants of cytochrome P450 2C9 modify the interaction between nonsteroidal anti-inflammatory drugs and coumarin anticoagulants. Visser LE; van Schaik RH; van Vliet M; Trienekens PH; De Smet PA; Vulto AG; Hofman A; van Duijn CM; Stricker BH Clin Pharmacol Ther; 2005 Jun; 77(6):479-85. PubMed ID: 15961979 [TBL] [Abstract][Full Text] [Related]
7. Influence of CYP2C9 genetic variants on gastrointestinal bleeding associated with nonsteroidal anti-inflammatory drugs: a systematic critical review. Estany-Gestal A; Salgado-Barreira A; Sánchez-Diz P; Figueiras A Pharmacogenet Genomics; 2011 Jul; 21(7):357-64. PubMed ID: 21597400 [TBL] [Abstract][Full Text] [Related]
8. Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Agúndez JA; García-Martín E; Martínez C Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):607-20. PubMed ID: 19422321 [TBL] [Abstract][Full Text] [Related]
9. The influence of polymorphisms of VKORC1 and CYP2C9 on major gastrointestinal bleeding risk in anticoagulated patients. Montes R; Nantes O; Alonso A; Zozaya JM; Hermida J Br J Haematol; 2008 Dec; 143(5):727-33. PubMed ID: 18950464 [TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C9 genotype on pharmacokinetics: are all NSAIDs the same? van Oijen MG; Laheij RJ Gastroenterology; 2007 Dec; 133(6):2073-4; author reply 2074-5. PubMed ID: 18054587 [No Abstract] [Full Text] [Related]
12. Major bleeding during combined treatment with indomethacin and low doses of acenocoumarol in a homozygous patient for 2C9*3 variant of cytochrome p-450 CYP2C9. Zarza J Thromb Haemost; 2003 Jul; 90(1):161-2. PubMed ID: 12876643 [No Abstract] [Full Text] [Related]
13. Use of analgesics and nonsteroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Fortuny J; Kogevinas M; Garcia-Closas M; Real FX; Tardón A; Garcia-Closas R; Serra C; Carrato A; Lloreta J; Rothman N; Villanueva C; Dosemeci M; Malats N; Silverman D Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1696-702. PubMed ID: 16985032 [TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms and the cardiovascular risk of non-steroidal anti-inflammatory drugs. St Germaine CG; Bogaty P; Boyer L; Hanley J; Engert JC; Brophy JM Am J Cardiol; 2010 Jun; 105(12):1740-5. PubMed ID: 20538124 [TBL] [Abstract][Full Text] [Related]
15. No modification of the beneficial effect of NSAIDs on colorectal cancer by CYP2C9 genotype. Siemes C; Eijgelsheim M; Dieleman JP; van Schaik RH; Uitterlinden AG; van Duijn CM; Hofman A; Coebergh JW; Stricker BH; Visser LE Neth J Med; 2009 Apr; 67(4):134-41. PubMed ID: 19581657 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influence dose requirements and stability of anticoagulation. Tàssies D; Freire C; Pijoan J; Maragall S; Monteagudo J; Ordinas A; Reverter JC Haematologica; 2002 Nov; 87(11):1185-91. PubMed ID: 12414349 [TBL] [Abstract][Full Text] [Related]
17. Cytochrome P4502C9 genotype in Southeast Anatolia and possible relation with some serum tumour markers and cytokines. Yilmaz N; Erbağci AB; Aynacioğlu AS Acta Biochim Pol; 2001; 48(3):775-82. PubMed ID: 11833786 [TBL] [Abstract][Full Text] [Related]
18. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461 [TBL] [Abstract][Full Text] [Related]
19. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789 [TBL] [Abstract][Full Text] [Related]
20. [Significance of cytochrome P450 2C9 genotype for the bleeding complications in patients treated with acenocoumarol]. Márk L; Márki-Zay J; Fodor L; Kondacs A; Paragh G; Katona A Orv Hetil; 2005 Apr; 146(16):739-43. PubMed ID: 15889670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]